A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Completely Protective Multivalent Mucosal Dual Vaccine Against COVID-19 and Flu
Jingen Zhu,Jian Sha,Himanshu Batra,Swati Jain,Xiaorong Wu,Emily Hendrix,Paul B Kilgore,Keer Sun,Kenneth S Plante,Jessica A Plante,Jordyn Walker,Pan Tao,Ashok K Chopra,Venigalla B Rao
DOI: https://doi.org/10.1101/2024.10.09.617418
2024-01-01
Abstract:The ongoing COVID-19 pandemic and recurrent influenza epidemics underscore the need for improved vaccine strategies, as the current vaccines face several challenges including limited mucosal protection, reduced efficacy against new variants, and waning immunity. We present an innovative bacteriophage T4 nanoparticle-based vaccine design that simultaneously targets both SARS-CoV-2 and influenza. It integrates three promising approaches: intranasal delivery for mucosal immunity, incorporation of multiple conserved antigens for broader protection, and nanoparticle presentation for enhanced B cell responses. By leveraging in vivo CRISPR genome engineering and in vitro SpyCatcher-SpyTag conjugation, this 120 x 86 nm T4-CoV-Flu vaccine nanoparticle incorporates 100s of antigen molecules from both pathogens, including SARS-CoV-2 spike ectodomain trimers, influenza hemagglutinin stem domain trimers, and M2e peptides on the capsid surface, while encapsulating matrix or nucleocapsid proteins inside. Intranasal administration of two doses of adjuvant-free T4-CoV-Flu vaccine to mice induced robust immune responses including high-titer IgG, secretory IgA, and neutralizing antibodies, balanced Th1/Th2 responses, and strong effector and memory T cell responses in both systemic and mucosal compartments. Notably, the vaccine elicited lung-resident CD8+ T cells, diverse memory B cell populations, and conferred complete protection against lethal challenges with both SARS-CoV-2 and influenza viruses. Furthermore, the T4 platform's rapid adaptability allowed vaccine candidate generation in 2-3 weeks. Coupled with its scalability in bacterial systems, thermostability, and adjuvant- and needle-free delivery, T4 thus presents an extraordinary platform to design potent mucosal vaccines against pandemic threats, and to bring vaccine access to resource-limited settings across the globe. ### Competing Interest Statement The authors have declared no competing interest.